OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologicsBusiness Overview: OSSPL is a subsidiary of Strides Pharma Ltd. The...
OneSource reports strong Q1FY27 results: Revenue ₹449.0 Cr (+37% YoY), EBITDA ₹123.3 Cr (+39% YoY), PAT ₹63.7 Cr (+72% YoY). Growth driven by semaglutide launch & new client wins. Second cartridge line commercializing Q2; biologics pipeline growing. FY28 guidance of $400M organic revenue reaffirmed.
OneSource Specialty Pharma has allotted 24,190 equity shares via ESOPs. This issuance increases the company's paid-up share capital from ₹11.46 Cr to ₹11.47 Cr and the total outstanding shares by 24,190.
OneSource saw strong Q4FY26 performance with Revenue at ₹428.2 Cr (+47% QoQ) and EBITDA at ₹91.9 Cr (5x+ QoQ), driven by semaglutide launches. It reaffirms FY28 guidance of ~₹3596 Cr organic revenue and 40% EBITDA margin. Steriscience asset acquisition is paused until post FY28.
OneSource Pharma's Board decided to postpone the SteriScience facilities acquisition. The merger plan, previously approved, will be revisited after both companies achieve their FY28 guidance, highlighting a strategic delay in business integration.
OneSource Pharma allotted 3,150 new equity shares via ESOP 2021. This led to a slight increase in its paid-up share capital, now standing at INR 11.46 Cr, for employee incentives.
